Impact Of Medicaid Prior Authorization On Angiotensin-Receptor Blockers: Can Policy Promote Rational Prescribing?
Open Access
- 1 May 2007
- journal article
- Published by Health Affairs (Project Hope) in Health Affairs
- Vol. 26 (3) , 800-807
- https://doi.org/10.1377/hlthaff.26.3.800
Abstract
Prescription drug cost containment is a key health policy priority. State Medic-aid programs have implemented policies requiring prior authorization before paying for angiotensin-receptor blockers (ARBs), a costly class of blood pressure medications. We examined the impact of these policies on drug use. We found that policies using a stepped-therapy approach reduced ARB use by 1.6 percent when first implemented and decreased the subsequent trend in ARB use by 1.3 percent per quarter; alternative approaches were unsuccessful. These findings have important implications for the development of rational drug reimbursement policy under Medicare Part D and other health insurance plans.Keywords
This publication has 10 references indexed in Scilit:
- Differential Effect of Early or Late Implementation of Prior Authorization Policies on the Use of Cox II InhibitorsMedical Care, 2006
- Heart Disease and Stroke Statistics—2006 UpdateCirculation, 2006
- The Implications of ChoiceArchives of internal medicine (1960), 2006
- Medicaid Prior-Authorization Programs and the Use of Cyclooxygenase-2 InhibitorsNew England Journal of Medicine, 2004
- Effects of a prior-authorization policy for celecoxib on medical service and prescription drug use in a managed care medicaid populationClinical Therapeutics, 2004
- Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or BothNew England Journal of Medicine, 2003
- The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureThe JNC 7 ReportJAMA, 2003
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic NephropathyNew England Journal of Medicine, 1993